Interleukin (IL)-
The paradox of IL-4 in tumor immunity
Three years after the cloning of IL-4 gene (1, 2), Tepper et al. expressed this molecule in two tumor cell lines, plasmacytoma J558L and mammary adenocarcinoma K485 (3) . Exciting things happened. All J558L tumors producing high amounts of IL-4 and 80% of J558L tumors producing low amounts of IL-4 were rejected, while the parental tumors, from which IL-4-secreting tumor cells were derived, and the mock tumors, which also carried the genetically introduced vector but did not produce IL-4, grew rapidly. Tumors that occasionally escaped the influence of IL-4 were found to lose IL-4 genes. Simultaneously, the growth of IL-4-producing K485 tumors was also inhibited, even in the T cell-deficient nu/nu mice (3). Mice rejected IL-4-secreting tumors got a long-lasting anti-tumor immunity and rejected subsequent challenge of parental tumor cells (4) . Interestingly, inoculation of IL-4-secreting tumors led to the rejection of non-related tumors without IL-4 producing ability in mixed tumor transplantation experiment (3) . In the following years, IL-4, as a potent anti-tumor agent, was demonstrated in different tumor models, including renal cancer (4), colorectal cancer (4, 5) , spontaneous adenocarcinoma (6), colon carcinoma (7, 8) , fibrosarcoma (9, 10) and melanoma (9) . Okada et al. compared the anti-tumor abilities of several cytokines using rat glioma (11) . They transferred the cDNA of granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon alpha (IFN), IL-12 and IL-4 into rat 9 L tumor cells. Then, they immunized rats by intradermal injection of 2 × 10 6 9L cells producing the above cytokines and 28 days later, challenged these rats with 1 × 10 5 parental 9 L tumor cells. Ninty percent rats vaccinated with 9L-IL-4 survived a subsequent challenge of parent tumor cells, much more than rats vaccinated with cells producing other cytokines (40% or 0%). Moreover, IL-4 was also the most effective among the cytokines in a therapeutic model as 43% of rats bearing 3-day 9L tumors survived >100 days after 9L-IL-4 treatment. In contrast, none of rats survived longer than 43 day after other treatment (9L-IL-12, 9L-IFN or 9L-GM-CSF) or control treatment (9L-neo or HBSS) (11). Pericle et al. had a similar observation using spontaneous adenocarcinoma TS/A (6). They found TS/A-IL-4 elicited a more efficient protective immunity against subsequent parental tumor cell challenge than TS/A-IL-2 (6).
These observations seem to point out a way to cure cancer patients with IL-4. However, clinical outcomes were disappointing (12) (13) (14) . In fact, cancer patients usually exhibited increased IL-4 level in tumor environment, and their lymphocytes, no matter peripheral blood lymphocytes or tumor infiltrating lymphocytes, were mostly polarized to secrete IL-4, as well as other Th2 cytokines. Shurin et al. summarized the data from plenty of clinical studies that investigated Th1/Th2 balance in cancer patients. They found IL-4, as well as other Th2 cytokines, was usually up-regulated in patients with different types of cancers, such as renal cell cancer, non-small lung cancer, prostate cancer, colon cancer, breast cancer and other types of tumors (15) . Onishi et al. even found the IL-4 amount at tumor site was associated with the stage and grade of renal cancer (16) .
The tumor-boosting effects of IL-4 were further confirmed by animal tumor models. EL4-B7-2, a murine lymphoma with the expression of costimulatory molecular B7-2, grew progressively in wild type mice, but was rejected by IL-4 knockout mice (17) . LL-LCMV, a derivative of Lewis lung carcinoma that has been modified to express a minigene encoding LCMV33-41, exhibited delayed growth in IL-4 knockout (18) . The evidence indicates IL-4 may provide some kind of help for tumor growth in vivo.
Even worse, IL-4 promotes tumor metastasis (19). Kobayashi et al. found the high metastatic variant of B16 melanoma (B16F10) induced a CD4
+ T cell population with strong IL-4-producing ability compared with T cells induced by the low metastatic variant, B16F1. Systemic IL-4 administration increased the metastasis of B16F1 to the level of B16F10. Neutralization of IL-4 using IL-4 specific mAb decreased the metastasis of B16F10 to the level of B16F1 (19) .
How can IL-4 have opposite effects on tumor growth? It is really an interesting question.
Exogenous and endogenous IL-4
According to the sources, IL-4 utilized by the above studies can be divided into two groups, exogenous and endogenous IL-4. Endogenous IL-4 refers to the IL-4 molecules that are generated without human intervention in a physiological or pathological process. Endogenous IL-4 is usually produced by T cells, basophiles and mast cells and its production is strictly regulated by various interacting signals (20, 21) . The facts, such as which cells produce, when and how much to produce, are mostly unknown now, but presumably should be carefully orchestrated to achieve homeostasis of immune system. In contrast, exogenous IL-4 is either systemically delivered as recombinant protein into the hosts (12, 14) or expressed locally by gene-modified tumor cells (3) . In gene-modified tumor cells, the promoters controlling IL-4 expression are usually strong viral promoters or promoters of the house keeping genes, which lead to persistent IL-4 production in copious amount. So, in the situation implanting IL-4-gene-modified tumor cells into hosts, tumor site would have large amount of IL-4 from the moment tumor begins to grow.
Besides, the cells producing endogenous IL-4 are mobile and they may secret IL-4 both in the tumor site and in lymph nodes where the antigen presentation takes place. In contrast, for IL-4-gene-modified tumors, IL-4 production is restricted at tumor site. Analyzing the roles of endogenous IL-4 will help us to understand the physiological role of this cytokine during tumor development, whereas analyzing the roles of exogenous IL-4 is useful for developing novel strategies for tumor therapy.
By summarizing the available studies to date, we find the positive, or negative roles of IL-4 in tumor immunity are closely associated with its sources, with endogenous IL-4 promoting, while exogenous IL-4 often suppressing tumor growth. In the following parts, we will review the actions of IL-4 on various types of cells in tumor environment and the underlying mechanisms of IL-4 promoting or suppressing tumor growth. Hereafter, exogenous IL-4 is specifically referred to IL-4 produced by genetically modified tumor cells.
The mechanism of exogenous IL-4-induced tumor rejection
In early studies performed by Tepper et al., eosinophils were thought to be the primary effectors responsible for tumor rejection (3). This type of cells, as well as macrophages, existed in abundant amount in IL-4 secreting tumor site. Depletion of eosinophils using the mAb RB6-8C5 (Anti-Gr1, a myeloid differentiation antigen) restored the growth of IL-4-secreting tumor in BALB/c mice (22) . However, the idea of considering eosinophils as the primary effectors encountered a little trouble when people found that tumor cells engineered to secrete IL-5 induced abundant eosinophil infiltration, but could not be rejected (23) . In fact, besides eosinophils, neutrophils were also present at IL-4-producing tumor site (6) . The antigen recognized by RB6-8C5 is expressed on both eosinophils and neutrophils (22) . In the cell-depletion experiments performed by Tepper, RB6-8C5 treatment simultaneously depleted eosinophils and neutrophils. It cannot be excluded that eosinophils were just by-standers, while neutrophils were the true effectors. This idea was eventually substantiated in 1993 by Noffz et al. (9) . They found eosinophil-deficient IL-5 -/-mice exhibited similar ability to suppress IL-4-secreting tumor as wild type mice. In these mice, no eosinophils, but many neutrophils were detected in tumor mass. Depletion of these neutrophils using RB6-8C5 partly restored tumor growth (9) .
The recognition of T cell contribution in exogenous IL-4-induced tumor rejection is also an uneven way. T, B and NK cells) and NIH III mice (also deficient of T, B and NK cells) (24) . Nonetheless, a long latency (about 30 days) existed before tumor nodule became palpable in these immuno-compromised mice. In immuno-competent mice, no tumor grew out. Cell depletion study indicated that CD8 + T lymphocyte were important, whereas CD4 + T cells played only a marginal role (24) . At present, a biphasic mechanism is considered to be operating for exogenous IL-4-induced tumor rejection during which a rapid, innate immune cell dominant inflammatory response inhibited tumor burden, whereby allowing T cells to be activated and to finally complete tumor rejection (Figure 1) .
Besides immune cells, IL-4 also acts on endothelial cells, inhibiting tumor-induced vascularization and starving tumor cells. Basic fibroblast growth factor (bFGF) is a potent inducer of angiogenesis and mounted a vigorous angiogenic response when implanted into the avascular cornea of rats as hydron pellet (25) . However, the angiogenesis was completely blocked by IL-4. When anti-IL-4 mAb was added, new blood vessels formed again (25) . In vitro, IL-4 inhibited the migration of cultured bovine and human microvascular cells and suppressed the formation of tube-like structure by human umbilical vein endothelial cells (HUVEC) induced by vascular endothelial growth factor (VEGF) and bFGF (26) . Moreover, Saleh et al. observed that IL-4-induced inhibition of C6 rat glioma was accompanied by reduced levels of vascularization (27, 28) . Practically, multiple factors, including innate immune cells, T lymphocytes and angiostasis may contribute to tumor rejection mediated by exogenous IL-4.
Endogenous IL-4 deviates host immune response to an ineffective status
It is well known that according to the cytokine profiles, CD4 + T cells are divided into Th1, which produces IFNγ, IL-2 and tumor necrosis factor beta (TNF), and Th2, which produces IL-4, IL-5, IL-6, IL-9 and IL-13. These two types of T cells are cross-inhibitory. IFNγ and IL-12 promote the generation of Th1 cells and inhibit Th2 cell development. Contrarily, IL-4 drives the development of Th2 cells and inhibits Th1 response (29, 30) .
Since the discovery of Th1 and Th2 cells by Mosmann in 1986 (31), their impacts on infection, allergy, autoimmune disease and transplantation etc have been extensively studied (15) . In tumor immunity, Th2-dorminant immune response often fails to protect hosts from tumor growth. Lee et al. low cells that were poorly cytolytic and expressed low levels of perforin and granzyme A, B and C (35, 36) .
It is possible that the endogenous IL-4, on one side, acts on CD4 + T cells to stabilize the Th2 status, on the other side, acts on CD8 + T cells to render them non-cytotoxic ( Figure 2 ). Of course, other mechanisms may also have some contributions, such as IL-10, which is a Th2 cytokine and induced by IL-4 and has been shown to have suppressive effects on tumor immunity.
However, things are often not so simple. Some studies have shown that IL-4-induced CD8 + Tc2 cells still remain, sometimes even have increased cytotoxicity (37) (38) (39) (40) . So, the effects of IL-4 on CD8 + T cells may rely on the initial cell status, the presence of other cytokines and the stimulating methods. IL-4 binding affinity also exhibits large amount of differences between tumor and normal cells. On tumor cells, the dissociation constants (Kd) are usually > 100, and sometimes reach 1000 (breast cancer), while on normal cells, it is usually < 100 (53) . To investigate IL-4R expression in situ, many immunohistological studies were done. In 12 normal and malignant specimens from human pancreas, only one of 5 normal pancreases showed weak to moderate positive staining for IL-4R. In contrast, all seven cancer specimens exhibited much more intensive staining (52) . Fifty-four lung tumor samples were also analyzed for IL-4R expression. Between 66 and 79% samples were positive for IL-4R staining, whereas normal lung tissues only showed weak staining (45) .
Tumor cells express elevated amount of IL-4R
Why have tumor cells increased IL-4R expression? According to the immunosurveillance theory, tumor initiation and progression are accompanied by the attack from host immune system (54) With these observations in normal B/T cells, it is easy to imagine that IL-4 promotes the survival of B/T cell-derived tumors. As early as in 1992, Danceca reported that IL-4 inhibited spontaneous and hydrocortisone-induced cell death of malignant B cells purified from patients with B chronic lymphocytic leukemia (67) .
Besides immune cells, IL-4 also protects other types of cells from apoptosis. Thyrocytes from patients with Grave diseases, a type of hyperthyroidism characterized by increased vascularization and enlargement of thyroid, express both CD95 and CD95L (68, 69) . But these cells are resistant to anti-CD95 monoclonal antibody-induced apoptosis. Longterm culture (4 days) sensitized them to apoptosis again, accompanied by the disappearance of cellular Bcl-x L and cFLIP. IL-4 presence in the long-term culture maintained Bcl-x L and cFLIP level and led to resistance of thyrocytes to apoptosis (68) .
Thyroid cancer is a type of malignancy arisen from thyroid epithelial. Stassi et al. demonstrated thyroid cancer cells showed refractoriness to chemotherapeutic agents including cisplatin, doxorubicin and taxol treatment (70) . Todaro found cancer cells from papillary, follicular or undifferentiated anaplastic thyroid carcinoma were resistant to CD95-induced apoptosis (71) . All these effects were IL-4-dependent (70, 71) . Other cancer cells, such as human bladder cancer cell RT112, prostate cancer cell LNCap and breast cancer cell MDA-MB-231 also exhibited IL-4-dependent apoptosis resistance (72) . In the presence of IL-4, these cells expressed high levels of cellular Bcl-x L , cFLIP or both of them. The investigators in our group observed the similar effects of IL-4 on murine fibrosarcoma (56) , and using IL-4R competent or deficient tumor cells of the same origin demonstrated that IL-4 promotes tumor growth in vivo (Figure 2 ).
The expression time and dose may determine the effects of IL-4 on tumor growth
Why can the same molecule have opposite effects on tumor growth? Maybe the different expression patterns, including dose and time, result in the different effects. Actually, opposite effects of low and high dose IL-4 had been demonstrated by Volpert (25) . They studied the migration of bovine adrenal capillary endothelial cells and human dermal capillary endothelial cells in the presence of a wide range (10 -3 -10 2 ng/ml) IL-4. The effects of IL-4 exhibited a biphasic modality with low concentration (10 -3 -10 -2 ng/ml) promoting and high concentration (10 -1 -10 2 ng/ml) inhibiting endothelial cell migration (25) .
Recently, our group is studying the time and dose effects of IL-4 expression on tumor growth. We inserted IL-4 cDNA into the downstream of a Tet-regulated promoter and transfected the fibrosarcom MCA205 cells with this IL-4 expressing plasmid. IL-4 expression by MCA205 tumor cells is easy to be regulated by adding Tet to the culturing medium (in vitro) or by supplying mice with drinking water containing different concentrations of Tet (in vivo). Our data showed clearly that IL-4-mediated tumor rejection is strictly dose-dependent. Furthermore, we found early IL-4 expression was able to (before day 5 after tumor cell inoculation), but late IL-4 expression failed to suppress the growth of s.c. inoculated tumors. Abundant granulocyte infiltrations were observed in both tumor nodules with early or late IL-4 expression. However, the granulocytes in mice with late IL-4 expression had cell surface markers characteristic for myeloid-derived suppressor cells (MDSC), a cell population with tumor-promoting effects, whereas in mice with early IL-4 expression, they appear to be mature granulocytes (manuscript submitted). 
Conclusions and future directions

